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1087JACC Vol. 47, No. 5, 2006 Correspondence
March 7, 2006:1082–90Second, we previously demonstrated that intravascular ultra-
ound is able to depict significant underlying mechanical problems
n most patients with ST (stent underexpansion, malapposition,
issections, inflow/outflow stenoses) (2). Because these findings,
hich require specific therapy, are frequently undetected by angiog-
aphy, a description of the ultrasonic data of these patients (if
vailable) would be helpful. Third, information on the reason for
nitial stent implantation would be appreciated because it has been
uggested that acute coronary syndromes (with the associated
latelet hyperactivity) may be a predisposing factor for ST (2).
Moreover, detailing whether some episodes of ST were second-
ry to antiplatelet therapy withdrawal would also be of great
nterest.
Finally, considering the potentially catastrophic consequences of
ecurrent ST, it would be important to define precisely when
lopidogrel therapy was discontinued in the study in order to
valuate platelet aggregation with aspirin alone. The potential
enefit of a higher dose of clopidogrel has been suggested (3,4),
nd this strategy appears especially attractive for high-risk patients.
herefore, from a pragmatic standpoint, it will be critical to
etermine whether the relative inefficacy of a conventional clopi-
ogrel regimen (1) can be overcome with higher doses (3,4).
ventually, unraveling the multifaceted etiology of ST is urgently
equired to prevent and successfully treat this challenging problem.
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EPLY
e thank Dr. Alfonso for his interest in our work (1). We agree
ith him that the phenomenon of “stent thrombosis” is a multi-
actoral process and that mechanical factors play an important role,
specially in the setting of an acute stent thrombosis (within 24 h),
hereas for subacute (1 to 30 days) or late stent thrombosis (30
ays) a more complex etiology has been postulated. In our case-
ontrol study no patient with an acute stent thrombosis was
ncluded (1). Platelet aggregation was assessed several months aftertent thrombosis to avoid confounding factors such as platelet
ctivation induced by thrombotic stent occlusion. Dr. Alfonso cites
our issues in his letter. We address each one here.
First, we fully agree that an optimal angiographic result is a key
actor in the prevention of stent thrombosis (2). In our study
opulation two patients showed a suboptimal angiographic result
one had a distal residual dissection with Thrombolysis In Myo-
ardial Infarction [TIMI] flow grade 2; another showed a no-
eflow phenomenon).
Second, intravascular ultrasound was not routinely performed
fter stent implantation in our institution. Therefore, we cannot
xclude stent underexpansion or stent malapposition.
Third, acute coronary syndromes have been previously identi-
ed as potential risk factors for stent thrombosis (2,3). In our study
opulation, 83% of the patients in the stent thrombosis group
uffered from an acute coronary syndrome at time of stent
mplantation, whereas only 43% of patients in the control group
ere affected (p  0.001). This highlights the importance of
ctivated platelets in the setting of an acute coronary syndrome and
he role of an effective antithrombotic regimen in the prevention of
tent thrombosis. Therefore, a resistance to antiplatelet therapy
ay represent an additional risk factor for stent thrombosis.
Fourth, all patients in our study population were on lifelong
spirin therapy; however, at the time of stent thrombosis 26% were
ff thienopyridine treatment. We agree that this may be another
isk factor, although the rate of clopidogrel resistance was lowest in
tent thrombosis patients. According to our protocol all patients
ere first examined under aspirin therapy alone, followed by a
econd measurement under aspirin and clopidogrel.
Finally, the etiology of stent thrombosis is multifaceted, and we
gree that mechanical risk factors should be avoided. Nevertheless,
he efficacy of our standard (dual) antiplatelet treatment might not
e as good as wished for. A higher dose of clopidogrel or new
ntithrombotic drugs as alternative treatment in patients with
esistance to antiplatelet therapy warrant further evaluation to
revent stent thrombosis and its high morbidity and mortality.
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